BioCentury | Nov 10, 2017
Regulation

Regulation relocation

Moving EMA’s headquarters hundreds of miles in a 16-month period is a mammoth task, considering it took the agency three years to move addresses from one end of London’s Canary Wharf to another. The move,...
BioCentury | Oct 10, 2013
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Bacterial cytological profiling (BCP) to identify the mechanism of action for antibacterial compounds Fluorescence imaging-based BCP can help identify the mechanism of action for...
BioCentury | Nov 20, 2006
Company News

BalChem Corp., CureMark deal

CureMark received an exclusive license to BCP's PharmaShure drug delivery technology for use in CureMark's digestive and pancreatic enzyme products. The company expects its lead products in autism and cystic fibrosis (CF) to enter the...
BioCentury | Jul 26, 2004
Company News

IsoTis OrthoBiologics sales and marketing update

ISON launched in the U.S. its OsSatura tri-calcium phosphate (TCP), a synthetic bone graft substitution. OsSatura TCP has faster resorption time than the existing OsSatura bi-calcium phosphate (BCP). OsSatura TCP has FDA 510(k) clearance, as...
BioCentury | Jan 13, 2003
Company News

IsoTis S.A. biomaterial/skin/wound news

ISON said it will reduce headcount by 31% to about 107 FTEs and restructure its R&D, in an effort to reduce its burn rate to E14 million ($14.6 million) in 2003 from E27 million ($28...
BioCentury | Jan 7, 2003
Company News

IsoTis restructuring

Tissue engineering company IsoTis (SWX:ISON; Euronext:ISON) said it will reduce headcount by 31% to about 107 FTEs and restructure its R&D in an effort to reduce its burn rate to EUR 14 million ($14.6 million)...
Items per page:
1 - 6 of 6